Barre verticale Université de Lausanne - Unisciences
 
 
Séparateur Annuaire Séparateur Actualités Séparateur Aide Séparateur Login
Langues:  fr | en
Transparent
RECHERCHE
Transparent
Transparent
Transparent
Photo ambiance
UNIL > Unisciences >
MyUNIL
Transparent
AFFICHER LES DONNEES
Transparent
de à
Données actuelles
Transparent

Monika Hegi

Coordonnées Curriculum Recherches Publications  
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


144 publications

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1995 | 1994 | 1993 | 1992 | 1990 | 1989 | 1987 |
 
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
Mansouri A., Hachem L.D., Mansouri S., Nassiri F., Laperriere N.J., Xia D., Lindeman N.I., Wen P.Y., Chakravarti A., Mehta M.P. et al., 2018/09/05. Neuro-oncology. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_1E3C16F37527]
 
Glioma epigenetics: From subclassification to novel treatment options.
Gusyatiner O., Hegi M.E., 2018/08. Seminars in cancer biology, 51 pp. 50-58. Peer-reviewed.
 
In vivo characterization of brain metabolism by <sup>1</sup> H MRS, <sup>13</sup> C MRS and <sup>18</sup> FDG PET reveals significant glucose oxidation of invasively growing glioma cells.
Lai M., Vassallo I., Lanz B., Poitry-Yamate C., Hamou M.F., Cudalbu C., Gruetter R., Hegi M.E., 2018/07/01. International journal of cancer, 143 (1) pp. 127-138. Peer-reviewed.
 
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M., Ono T., Stichel D., Schrimpf D., Reuss D.E., Sahm F., Koelsche C., Wefers A., Reinhardt A., Huang K. et al., 2018/07. Acta neuropathologica, 136 (1) pp. 153-166. Peer-reviewed.
 
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Gao Y., Weenink B., van den Bent M.J., Erdem-Eraslan L., Kros J.M., Sillevis Smitt P., Hoang-Xuan K., Brandes A.A., Vos M., Dhermain F. et al., 2018/05. European journal of cancer, 94 pp. 168-178. Peer-reviewed.
 
Toward methylation-based classification of central nervous system tumors.
Hegi M.E., Kleihues P., Wen P.Y., Suvà M.L., 2018/04/09. Neuro-oncology, 20 (5) pp. 579-581. Peer-reviewed.
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Bady P., Kurscheid S., Delorenzi M., Gorlia T., van den Bent M.J., Hoang-Xuan K., Vauléon É., Gijtenbeek A., Enting R., Thiessen B. et al., 2018/04. Acta neuropathologica, 135 (4) pp. 601-615. Peer-reviewed.
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R., Taillibert S., Kanner A., Read W., Steinberg D.M., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K. et al., 2017/12/19. JAMA, 318 (23) pp. 2306-2316. Peer-reviewed.
Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.
Oikonomaki M., Bady P., Hegi M.E., 2017/12/15. Oncotarget, 8 (66) pp. 110490-110502. Peer-reviewed.
Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff A.S., Kiesel B., Widhalm G., Wilhelm D., Rajky O., Kurscheid S., Kresl P., Wöhrer A., Marosi C., Hegi M.E. et al., 2017/10/19. Neuro-oncology, 19 (11) pp. 1460-1468. Peer-reviewed.
 
Evidence-based management of adult patients with diffuse glioma - Authors' reply.
Weller M., van den Bent M., Tonn J.C., Stupp R., Preusser M., Cohen-Jonathan-Moyal E., Henriksson R., Rhun E.L., Balana C., Chinot O. et al., 2017/08. The Lancet. Oncology, 18 (8) pp. e430-e431. Peer-reviewed.
 
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Blumenthal D.T., Gorlia T., Gilbert M.R., Kim M.M., Burt Nabors L., Mason W.P., Hegi M.E., Zhang P., Golfinopoulos V., Perry J.R. et al., 2017/08/01. Neuro-oncology, 19 (8) pp. 1119-1126. Peer-reviewed.
 
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.
Weller M., van den Bent M., Tonn J.C., Stupp R., Preusser M., Cohen-Jonathan-Moyal E., Henriksson R., Le Rhun E., Balana C., Chinot O. et al., 2017/06. The Lancet. Oncology, 18 (6) pp. e315-e329. Peer-reviewed.
Current management of low-grade gliomas.
Hottinger A.F., Hegi M.E., Baumert B.G., 2016/12. Current opinion in neurology, 29 (6) pp. 782-788. Peer-reviewed.
Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T.
Porcari P., Hegi M.E., Lei H., Hamou M.F., Vassallo I., Capuani S., Gruetter R., Mlynarik V., 2016/11. NMR in biomedicine, 29 (11) pp. 1577-1589. Peer-reviewed.
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Wick W., Gorlia T., Bady P., Platten M., van den Bent M.J., Taphoorn M.J., Steuve J., Brandes A.A., Hamou M.F., Wick A. et al., 2016/10/01. Clinical cancer research, 22 (19) pp. 4797-4806. Peer-reviewed.
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Weller M., Nabors L.B., Gorlia T., Leske H., Rushing E., Bady P., Hicking C., Perry J., Hong Y.K., Roth P. et al., 2016/03/22. Oncotarget, 7 (12) pp. 15018-15032. Peer-reviewed.
 
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Happold C., Gorlia T., Chinot O., Gilbert M.R., Nabors L.B., Wick W., Pugh S.L., Hegi M., Cloughesy T., Roth P. et al., 2016. Journal of Clinical Oncology, 34 (7) pp. 731-739. Peer-reviewed.
 
Glioblastoma, IDH wild-type
Louis D.N., Suvà M.L., Burger P.C., Kleihues P., Aldape K.D., . ..., Hegi M., . .., von Deimling A., 2016. pp. 28-45 dans Louis D.N., Ohgaki H., Wiestler O., Cavenee W.K. (eds.) WHO classification of tumours of the central nervous system, IARC.
 
Reply to F. Felix et al and M.F. Fay et al.
Happold C., Gorlia T., Chinot O., Gilbert M.R., Nabors L.B., Wick W., Pugh S.L., Hegi M., Cloughesy T., Roth P. et al., 2016. Journal of Clinical Oncology, 34 (25) pp. 3107-3108. Peer-reviewed.
Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
Bady P., Delorenzi M., Hegi M.E., 2016. Journal of Molecular Diagnostics, 18 (3) pp. 350-361. Peer-reviewed.
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert B.G., Hegi M.E., van den Bent M.J., von Deimling A., Gorlia T., Hoang-Xuan K., Brandes A.A., Kantor G., Taphoorn M.J., Hassel M.B. et al., 2016. Lancet. Oncology, 17 (11) pp. 1521-1532. Peer-reviewed.
WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1.
Vassallo I., Zinn P., Lai M., Rajakannu P., Hamou M.F., Hegi M.E., 2016. Oncogene, 35 (1) pp. 12-21. Peer-reviewed.
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.
Kurscheid S., Bady P., Sciuscio D., Samarzija I., Shay T., Vassallo I., Criekinge W.V., Daniel R.T., van den Bent M.J., Marosi C. et al., 2015. Genome Biology, 16 (1) p. 16. Peer-reviewed.
Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison.
De Meyer T., Bady P., Trooskens G., Kurscheid S., Bloch J., Kros J.M., Hainfellner J.A., Stupp R., Delorenzi M., Hegi M.E. et al., 2015. Scientific Reports, 5 p. 15375. Peer-reviewed.
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R., Taillibert S., Kanner A.A., Kesari S., Steinberg D.M., Toms S.A., Taylor L.P., Lieberman F., Silvani A., Fink K.L. et al., 2015. JAMA, 314 (23) pp. 2535-2543. Peer-reviewed.
Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
Sathyan P., Zinn P.O., Marisetty A.L., Liu B., Kamal M.M., Singh S.K., Bady P., Lu L., Wani K.M., Veo B.L. et al., 2015. Journal of Neuroscience, 35 (45) pp. 15097-15112. Peer-reviewed.
 
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.
Berghoff A.S., Kiesel B., Widhalm G., Rajky O., Ricken G., Wöhrer A., Dieckmann K., Filipits M., Brandstetter A., Weller M. et al., 2015. Neuro-oncology, 17 (8) pp. 1064-1075. Peer-reviewed.
 
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors L.B., Fink K.L., Mikkelsen T., Grujicic D., Tarnawski R., Nam do H, Mazurkiewicz M., Salacz M., Ashby L., Zagonel V. et al., 2015. Neuro-oncology, 17 (5) pp. 708-717. Peer-reviewed.
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Hegi M.E., Stupp R., 2015. Neuro-oncology, 17 (11) pp. 1425-1427. Peer-reviewed.
 
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Stupp R., Hegi M.E., Gorlia T., Erridge S.C., Perry J., Hong Y.K., Aldape K.D., Lhermitte B., Pietsch T., Grujicic D. et al., 2014. Lancet. Oncology, 15 (10) pp. 1100-1108. Peer-reviewed.
 
MGMT testing-the challenges for biomarker-based glioma treatment.
Wick W., Weller M., van den Bent M., Sanson M., Weiler M., von Deimling A., Plass C., Hegi M., Platten M., Reifenberger G., 2014. Nature Reviews. Neurology, 10 (7) pp. 372-385. Peer-reviewed.
 
Reply to M.C. Chamberlain.
Gilbert M.R., Dignam J., Pugh S., Armstrong T.S., Wefel J.S., Aldape K., Stupp R., Hegi M., Won M., Curran W.J. et al., 2014. Journal of Clinical Oncology, 32 (15) pp. 1634-1635.
 
Brain cancer in 2012: Molecular characterization leads the way.
Stupp R., Hegi M.E., 2013. Nature Reviews. Clinical Oncology, 10 (2) pp. 69-70.
 
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Gilbert M.R., Wang M., Aldape K.D., Stupp R., Hegi M.E., Jaeckle K.A., Armstrong T.S., Wefel J.S., Won M., Blumenthal D.T. et al., 2013. Journal of Clinical Oncology, 31 (32) pp. 4085-4091. Peer-reviewed.
 
Epigenetics and brain cancer
Sciuscio D., Hegi M.E., 2013. pp. 21-40 dans Watts C. (eds.) Emerging Concepts in Neuro-Oncology, Springer.
 
Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P., Sciuscio D., Diserens A.C., Bloch J., van den Bent M.J., Marosi C., Dietrich P.Y., Weller M., Mariani L., Heppner F.L. et al., 2013. Acta Neuropathologica, 126 (1) p. 159.
 
Molecular insights into brain tumors: ready for translation into novel treatment strategies?
Hegi M.E., 2013. Current Opinion in Neurology, 26 (6) pp. 678-680. Peer-reviewed.
 
Molecular neuro-oncology in clinical practice: a new horizon.
Weller M., Pfister S.M., Wick W., Hegi M.E., Reifenberger G., Stupp R., 2013. Lancet Oncology, 14 (9) pp. e370-e379. Peer-reviewed.
 
Neuro-oncology: In search of molecular markers of glioma in elderly patients.
Hegi M.E., Stupp R., 2013. Nature Reviews. Neurology, 9 (8) pp. 424-425.
 
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen T.C., Prestegarden L., Grudic A., Hegi M.E., Tysnes B.B., Bjerkvig R., 2013. Neuro-Oncology, 15 (3) pp. 269-278. Peer-reviewed.
A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature.
Zinn P.O., Sathyan P., Mahajan B., Bruyere J., Hegi M., Majumder S., Colen R.R., 2012. Plos One, 7 (8) pp. e41522.
 
A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon Multi-Platform Biomarker Profiles
Chakravarti A., Wang M., Aldape K., Sulman E., Bredel M., Hegi M., Gilbert M., Curran W., Werner-Wasik M., Mehta M., 2012. p. 134 dans 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, European Journal of Cancer.
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Nabors L.B., Mikkelsen T., Hegi M.E., Ye X., Batchelor T., Lesser G., Peereboom D., Rosenfeld M.R., Olsen J., Brem S. et al., 2012. Cancer, 118 (22) pp. 5601-5607. Peer-reviewed.
 
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
Agnihotri S., Gajadhar A.S., Ternamian C., Gorlia T., Diefes K.L., Mischel P.S., Kelly J., McGown G., Thorncroft M., Carlson B.L. et al., 2012. Journal of Clinical Investigation, 122 (1) pp. 253-266.
 
Clinical implications of molecular neuropathology and biomarkers for malignant glioma.
Tabatabai G., Hegi M., Stupp R., Weller M., 2012. Current Neurology and Neuroscience Reports, 12 (3) pp. 302-307.
 
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Bady P., Diserens A.C., Castella V., Kalt S., Heinimann K., Hamou M.F., Delorenzi M., Hegi M.E., 2012. Neuro-Oncology, 14 (6) pp. 701-711.
 
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
Franceschi E., Stupp R., van den Bent M.J., van Herpen C., Laigle Donadey F., Gorlia T., Hegi M., Lhermitte B., Strauss L.C., Allgeier A. et al., 2012. Neuro-Oncology, 14 (12) pp. 1503-1510.
 
EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology
Wicka Wolfgang, van den Bentb Martin, Vechtc Charles, Brandesd Alba, Lacombee Denis, Gorliae Thierry, Allgeiere Anouk, Baumertf Brigitta G., Soffiettig Riccardo, Sansonh Marc et al., 2012. European Journal of Cancer Supplements, 10 (Suppl. 1) pp. 20-26. Peer-reviewed.
 
Epidermal growth factor receptor: a re-emerging target in glioblastoma.
Hegi M.E., Rajakannu P., Weller M., 2012. Current Opinion In Neurology, 25 (6) pp. 774-779. Peer-reviewed.
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P., Sciuscio D., Diserens A.C., Bloch J., van den Bent M.J., Marosi C., Dietrich P.Y., Weller M., Mariani L., Heppner F.L. et al., 2012. Acta Neuropathologica, 124 (4) pp. 547-560. Peer-reviewed.
 
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.
Gorlia T., Stupp R., Brandes A.A., Rampling R.R., Fumoleau P., Dittrich C., Campone M.M., Twelves C.C., Raymond E., Hegi M.E. et al., 2012. European Journal of Cancer, 48 (8) pp. 1176-1184.
 
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
Weller M., Stupp R., Hegi M.E., van den Bent M., Tonn J.C., Sanson M., Wick W., Reifenberger G., 2012. Neuro-oncology, 14 Suppl 4 pp. iv100-iv108. Peer-reviewed.
 
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Hegi M.E., Janzer R.C., Lambiv W.L., Gorlia T., Kouwenhoven M.C., Hartmann C., von Deimling A., Martinet D., Besuchet Schmutz N., Diserens A.C. et al., 2012. Acta Neuropathologica, 123 (6) pp. 841-852. Peer-reviewed.
 
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A., Grønberg B.H., Marosi C., Stupp R., Frappaz D., Schultz H., Abacioglu U., Tavelin B., Lhermitte B., Hegi M.E. et al., 2012. Lancet Oncology, 13 (9) pp. 916-926. Peer-reviewed.
 
Treatment options in elderly patients with glioblastoma - Authors' reply.
Malmström A., Stupp R., Hegi M., Rosell J., Henriksson R., 2012. Lancet Oncology, 13 (11) pp. e461-e462.
 
A combined molecular clinical predictor of survival validated with the rtog-0525 cohort
Sulman E.P., Cahill D.P., Wang M., Won M., Hegi M.E., Mehta M.P., Aldape K.D., Gilbert M.R., 2011. p. 83 dans 2011 SNO 16th Annual Scientific Meeting in Conjunction with the AANS/CNS Section on Tumors, Neuro-Oncology. Peer-reviewed.
 
Clinical utility of g-cimp and idh1 status as dual prognostic markers in glioblastoma
Aldape K.D., Gilbert M., Cahill D., Wang M., Won M., Hegi M., Colman H., Mehta M., Sulman E., 2011. p. 84 dans 2011 SNO 16th Annual Scientific Meeting in Conjunction with the AANS/CNS Section on Tumors, Neuro-Oncology. Peer-reviewed.
 
Current concepts and management of glioblastoma.
Preusser M., de Ribaupierre S., Wöhrer A., Erridge S.C., Hegi M., Weller M., Stupp R., 2011. Annals of Neurology, 70 (1) pp. 9-21.
 
Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
Faoro D., von Bueren A.O., Shalaby T., Sciuscio D., Hürlimann M.L., Arnold L., Gerber N.U., Haybaeck J., Mittelbronn M., Rutkowski S. et al., 2011. Journal of Neuro-oncology, 103 (1) pp. 59-69. Peer-reviewed.
 
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.
Sciuscio D., Diserens A.C., van Dommelen K., Martinet D., Jones G., Janzer R.C., Pollo C., Hamou M.F., Kaina B., Stupp R. et al., 2011. Clinical Cancer Research, 17 (2) pp. 255-266.
 
Extent of resection in glioblastoma - variation between molecular risk groups in rtog-0525
Cahill D., Wang M., Won M., Aldape K., Maywald R., Hegi M., Mehta M., Gilbert M., Sulman E., Vogelbaum M., 2011. p. 160 dans 2011 SNO 16th Annual Scientific Meeting in Conjunction with the AANS/CNS Section on Tumors, Neuro-Oncology. Peer-reviewed.
 
IDH1/IDH2 mutations predict survival in glioma and AML
Hegi M., 2011. pp. S2 dans 5th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), American Society of Clinical Oncology (ASCO), Annual Meeting on Molecular Markers in Cancer, European Journal of Cancer. Peer-reviewed.
 
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
Hegi M.E., Diserens A.C., Bady P., Kamoshima Y., Kouwenhoven M.C., Delorenzi M., Lambiv W.L., Hamou M.F., Matter M.S., Koch A. et al., 2011. Molecular Cancer Therapeutics, 10 (6) pp. 1102-1112.
 
RTOG 0525: A randomized phase iii trial comparing standard adjuvant temozolomide (tmz) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (gbm)
Gilbert M.R., Wang M., Aldape K.D., Stupp R., Hegi M., Jaeckle K.A., Armstrong T.S., Wefel J.S., Won M., Blumenthal D.T. et al., 2011. p. 51 dans 2011 SNO 16th Annual Scientific Meeting in Conjunction with the AANS/CNS Section on Tumors, Neuro-Oncology. Peer-reviewed.
 
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.
Lambiv W.L., Vassallo I., Delorenzi M., Shay T., Diserens A.C., Misra A., Feuerstein B., Murat A., Migliavacca E., Hamou M.F. et al., 2011. Neuro-Oncology, 13 (7) pp. 736-747. Peer-reviewed.
 
Reply to M.C. Chamberlain
Stupp Roger, Hegi Monika E., Neyns Bart, Goldbrunner Roland, Schlegel Uwe, Clement Paul M.J., Grabenbauer Gerhard G., Ochsenbein Adrian F., Simon Matthias, Dietrich Pierre-Yves et al., 2010/11/20. Journal of Clinical Oncology, 28 (33) pp. e696-e697. Peer-reviewed.
 
MGMT promoter methylation in malignant gliomas.
Riemenschneider M.J., Hegi M.E., Reifenberger G., 2010/09. Targeted oncology, 5 (3) pp. 161-165. Peer-reviewed.
 
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Weller M., Wick W., Hegi M.E., Stupp R., Tabatabai G., 2010/09. Future oncology, 6 (9) pp. 1407-1414. Peer-reviewed.
 
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.
McDonald K.L., McDonnell J., Muntoni A., Henson J.D., Hegi M.E., von Deimling A., Wheeler H.R., Cook R.J., Biggs M.T., Little N.S. et al., 2010/07. Journal of neuropathology and experimental neurology, 69 (7) pp. 729-736. Peer-reviewed.
 
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R., Hegi M.E., Neyns B., Goldbrunner R., Schlegel U., Clement P.M., Grabenbauer G.G., Ochsenbein A.F., Simon M., Dietrich P.Y. et al., 2010/06/01. Journal of clinical oncology, 28 (16) pp. 2712-2718. Peer-reviewed.
 
Marker-independent identification of glioma-initiating cells.
Clément V., Marino D., Cudalbu C., Hamou M.F., Mlynarik V., de Tribolet N., Dietrich P.Y., Gruetter R., Hegi M.E., Radovanovic I., 2010/03. Nature methods, 7 (3) pp. 224-228. Peer-reviewed.
 
Longer survival for patients with alternative lengthening of telomeres (ALT) glioblastoma multiforme is due to a less aggressive phenotype and not to improved response to adjuvant therapy
McDonald K., McDonnell J., Muntoni A., Henson J., Hegi M., Wheeler H., Cook R., Biggs M., Little N., Robinson B. et al., 2010. p. 3 dans Meeting of the British Neuro-Oncology Society, Neuro-Oncology. Peer-reviewed.
 
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller M., Stupp R., Reifenberger G., Brandes A.A., van den Bent M.J., Wick W., Hegi M.E., 2010. Nature Reviews. Neurology, 6 (1) pp. 39-51.
 
Molecular diagnostics of gliomas: the clinical perspective.
Tabatabai G., Stupp R., Van Den Bent M.J., Hegi M.E., Tonn J.C., Wick W., Weller M., 2010. Acta Neuropathologica, 120 (5) pp. 585-592.
 
Neuro-oncology, a decade of temozolomide and beyond.
Stupp R., Hegi M., Weller M., 2010. Expert Review of Anticancer Therapy, 10 (11) pp. 1675-1677.
Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting.
Imaizumi N., Monnier Y., Hegi M., Mirimanoff R.O., Rüegg C., 2010. Plos One, 5 (6) pp. e11084.
Combining chromosomal arm status and significantly aberrant genomic locations reveals new cancer subtypes.
Shay T., Lambiv W.L., Reiner-Benaim A., Hegi M.E., Domany E., 2009. Cancer Informatics, 7 pp. 91-104. Peer-reviewed.
 
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K. et al., 2009. The lancet Oncology, 10 (5) pp. 459-466. Peer-reviewed.
 
Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome.
Shnaper S., Desbaillets I., Brown D.A., Murat A., Migliavacca E., Schluep M., Ostermann S., Hamou M.F., Stupp R., Breit S.N. et al., 2009. International Journal of Cancer, 125 (11) pp. 2624-2630. Peer-reviewed.
 
Epigenetic deregulation of DNA repair and its potential for therapy.
Hegi M.E., Sciuscio D., Murat A., Levivier M., Stupp R., 2009. Clinical Cancer Research, 15 (16) pp. 5026-5031. Peer-reviewed.
 
MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma
Aldape K.D., Jones G., Wang M., Hegi M., Janzer R.C., Stupp R., Mehta M.P., Gilbert M.R., 2009. pp. Abstract 2051 dans 45th Annual Meeting of the American Society of Clinical Oncology, Journal of Clinical Oncology. Peer-reviewed.
 
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent M.J., Dubbink H.J., Sanson M., van der Lee-Haarloo C.R., Hegi M., Jeuken J.W., Ibdaih A., Brandes A.A., Taphoorn M.J., Frenay M. et al., 2009. Journal of Clinical Oncology, 27 (35) pp. 5881-6. Peer-reviewed.
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.
Murat A., Migliavacca E., Hussain S.F., Heimberger A.B., Desbaillets I., Hamou M.F., Rüegg C., Stupp R., Delorenzi M., Hegi M.E., 2009. PloS One, 4 (6) pp. e5947. Peer-reviewed.
 
O6-Methylguanine DNA Methyltransferase (Mgmt) Promoter Methylation in Primitive Neuroectodermal Brain Tumor (Pnet) Correlates with MGMT RNA Expression and Sensitivity of PNET Cells to Temozolomide : PM.002
von Bueren Andre, Faoro Denis, Shalaby Tarek, Huerlimann Marie-Louise, Arnold Luzia, Gerber Nicolas, Haybaeck Johannes, Mittelbronn Michel, Hegi Monika, Rutkowski Stefan et al., 2009. p. 825 dans 41st Annual Conference of the International Society of Paediatric Oncology, Pediatric Blood & Cancer. Peer-reviewed.
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Beier C.P., Schmid C., Gorlia T., Kleinletzenberger C., Beier D., Grauer O., Steinbrecher A., Hirschmann B., Brawanski A., Dietmaier C. et al., 2009. BMC Cancer, 9 (1) p. 308. Peer-reviewed.
 
Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas.
Sivasankaran B., Degen M., Ghaffari A., Hegi M.E., Hamou M.F., Ionescu M.C., Zweifel C., Tolnay M., Wasner M., Mergenthaler S. et al., 2009. Cancer Research, 69 (2) pp. 458-465. Peer-reviewed.
 
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.
Preusser M., Charles Janzer R., Felsberg J., Reifenberger G., Hamou M.F., Diserens A.C., Stupp R., Gorlia T., Marosi C., Heinzl H. et al., 2008. Brain Pathology, 18 (4) pp. 520-532. Peer-reviewed.
 
Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment.
Lange K., Kammerer M., Saupe F., Hegi M.E., Grotegut S., Fluri E., Orend G., 2008. Cancer Research, 68 (17) pp. 6942-6952. Peer-reviewed.
 
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
Hegi M.E., Liu L., Herman J.G., Stupp R., Wick W., Weller M., Mehta M.P., Gilbert M.R., 2008. Journal of Clinical Oncology, 26 (25) pp. 4189-4199.
 
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.
Brandes A.A., Franceschi E., Tosoni A., Hegi M.E., Stupp R., 2008. Clinical Cancer Research, 14 (4) pp. 957-960. Peer-reviewed.
 
Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.
Voelter V., Diserens A.C., Moulin A., Nagel G., Yan P., Migliavacca E., Rimoldi D., Hamou M.F., Kaina B., Leyvraz S. et al., 2008. International Journal of Cancer, 123 (5) pp. 1215-1218. Peer-reviewed.
 
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Gorlia T., van den Bent M.J., Hegi M.E., Mirimanoff R.O., Weller M., Cairncross J.G., Eisenhauer E., Belanger K., Brandes A.A., Allgeier A. et al., 2008. The Lancet Oncology, 9 (1) pp. 29-38.
 
Stem cell-related &quot;self-renewal&quot; signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Murat A., Migliavacca E., Gorlia T., Lambiv W.L., Shay T., Hamou M.F., de Tribolet N., Regli L., Wick W., Kouwenhoven M.C. et al., 2008. Journal of Clinical Oncology, 26 (18) pp. 3015-3024.
 
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.
Vlassenbroeck I., Califice S., Diserens A.C., Migliavacca E., Straub J., Di Stefano I., Moreau F., Hamou M.F., Renard I., Delorenzi M. et al., 2008. Journal of Molecular Diagnostics, 10 (4) pp. 332-337. Peer-reviewed.
 
Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization
Lange K., Kammerer M., Hegi M. E., Grotegut S., Dittmann A., Huang W., Fluri E., Yip G. W., Gotte M., Ruiz C. et al., 2007/07. Cancer Research, 67 (13) pp. 6163-73.
 
Chemoradiotherapy in malignant glioma: standard of care and future directions.
Stupp R., Hegi M.E., Gilbert M.R., Chakravarti A., 2007. Journal of Clinical Oncology, 25 (26) pp. 4127-4136.
 
Methylguanine methyltransferase testing in glioblastoma: when and how?
Stupp R., Hegi M.E., 2007. Journal of Clinical Oncology, 25 (12) pp. 1459-1460.
MGMT methylation status: the advent of stratified therapy in glioblastoma?
Hau P., Stupp R., Hegi M.E., 2007. Disease markers, 23 (1-2) pp. 97-104. Peer-reviewed.
 
Neuro-oncology: oligodendroglioma and molecular markers.
Stupp R., Hegi M.E., 2007. Lancet neurology, 6 (1) pp. 10-2. Peer-reviewed.
 
Rôle de la MGMT et implications cliniques dans les tumeurs cérébrales [Role of MGMT and clinical applications in brain tumours]
Paus C., Murat A., Stupp R., Regli L., Hegi M., 2007. Bulletin du cancer, 94 (9) pp. 769-73.
 
Targeting brain-tumor stem cells.
Stupp R., Hegi M.E., 2007. Nature biotechnology, 25 (2) pp. 193-4. Peer-reviewed.
 
Brain tumors: molecular biology and targeted therapies
Hegi M. E., Murat A., Lambiv W. L., Stupp R., 2006/09. Annals of Oncology, 17 Suppl 10 pp. x191-7.
 
Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Preusser M., Heinzl H., Gelpi E., Schonegger K., Haberler C., Birner P., Marosi C., Hegi M., Gorlia T., Hainfellner J. A., 2006/07. Cancer, 107 (1) pp. 162-70.
 
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Stupp R., Hegi M.E., van den Bent M.J., Mason W.P., Weller M., Mirimanoff R.O., Cairncross J.G., and , 2006. Oncologist, 11 (2) pp. 165-180. Peer-reviewed.
 
Correlative studies in neuro-oncology trials: should they influence treatment?
Hegi M.E., Stupp R., 2006. Current Oncology Reports, 8 (1) pp. 54-57. Peer-reviewed.
 
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Dehdashti A.R., Hegi M.E., Regli L., Pica A., Stupp R., 2006. Neurosurgical Focus, 20 (4) pp. E6.
 
Recent developments in the use of chemotherapy in brain tumours.
van den Bent M.J., Hegi M.E., Stupp R., 2006. European Journal of Cancer (oxford, England : 1990), 42 (5) pp. 582-588. Peer-reviewed.
 
Optimal role of temozolomide in the treatment of malignant gliomas
Stupp R., van den Bent M. J., Hegi M. E., 2005/05. Current Neurology and Neuroscience Reports, 5 (3) pp. 198-206.
 
Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice
Kim Y., Hong H. H., Lachat Y., Clayton N. P., Devereux T. R., Melnick R. L., Hegi M. E., Sills R. C., 2005. Toxicologic Pathology, 33 (3) pp. 307-12.
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L. et al., 2005. New England Journal of Medicine, 352 (10) pp. 997-1003.
 
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi M.E., Diserens A.C., Godard S., Dietrich P.Y., Regli L., Ostermann S., Otten P., Van Melle G., de Tribolet N., Stupp R., 2004. Clinical Cancer Research, 10 (6) pp. 1871-1874. Peer-reviewed.
 
Growth promoting signaling by tenascin-C [corrected].
Ruiz C., Huang W., Hegi M.E., Lange K., Hamou M.F., Fluri E., Oakeley E.J., Chiquet-Ehrismann R., Orend G., 2004. Cancer Research, 64 (20) pp. 7377-7385. Peer-reviewed.
 
INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.
Lachat Y., Diserens A.C., Nozaki M., Kobayashi H., Hamou M.F., Godard S., De Tribolet N., Hegi M.E., 2004. Oncogene, 23 (41) pp. 6854-6863. Peer-reviewed.
 
Prognostic factors for low-grade gliomas
Stupp R., Janzer R. C., Hegi M. E., Villemure J. G., Mirimanoff R. O., 2003/12. Seminars in Oncology, 30 (6 Suppl 19) pp. 23-8.
 
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.
Godard S., Getz G., Delorenzi M., Farmer P., Kobayashi H., Desbaillets I., Nozaki M., Diserens A.C., Hamou M.F., Dietrich P.Y. et al., 2003. Cancer Research, 63 (20) pp. 6613-6625. Peer-reviewed.
 
Recent developments in the management of malignant glioma
Stupp R, Hegi M. E., 2003. pp. 779-788 dans Perry MC (eds.) ASCO 2003 Educational Book, American Society of Clinical Oncology.
 
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.
Albertoni M., Shaw P.H., Nozaki M., Godard S., Tenan M., Hamou M.F., Fairlie D.W., Breit S.N., Paralkar V.M., de Tribolet N. et al., 2002. Oncogene, 21 (27) pp. 4212-4219.
 
Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas
Labuhn M., Jones G., Speel E. J., Maier D., Zweifel C., Gratzl O., Van Meir E. G., Hegi M. E., Merlo A., 2001/03. Oncogene, 20 (9) pp. 1103-9.
 
p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade.
Nozaki M., Tada M., Kashiwazaki H., Hamou M.F., Diserens A.C., Shinohe Y., Sawamura Y., Iwasaki Y., de Tribolet N., Hegi M.E., 2001. Brain Pathology, 11 (3) pp. 296-305.
 
Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant
Klein M. A., Ruedi D., Nozaki M., Dell E. W., Diserens A. C., Seelentag W., Janzer R. C., Aguzzi A., Hegi M. E., 2000/11. Oncogene, 19 (47) pp. 5329-37.
 
p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma
Fulci G., Labuhn M., Maier D., Lachat Y., Hausmann O., Hegi M. E., Janzer R. C., Merlo A., Van Meir E. G., 2000/08. Oncogene, 19 (33) pp. 3816-22.
 
Gliosarcoma
Ohgaki H., Biernat W., Reis R., Hegi M., Kleihues P., 2000. pp. 42-44 dans Kleihues P., Cavenee W. K. (eds.) Pathology and genetics of tumours of the nervous system, IARCPress.
 
p53 transdominance but no gain of function in mouse brain tumor model.
Hegi M.E., Klein M.A., Rüedi D., Chène P., Hamou M.F., Aguzzi A., 2000. Cancer Research, 60 (11) pp. 3019-3024.
 
Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome
Chene P., Ory K., Ruedi D., Soussi T., Hegi M. E., 1999/07. International Journal of Cancer, 82 (1) pp. 17-22.
 
No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice.
Maddalena A.S., Hainfellner J.A., Hegi M.E., Glatzel M., Aguzzi A., 1999. Brain pathology (Zurich, Switzerland), 9 (4) pp. 627-37. Peer-reviewed.
 
Light-induced cell death of retinal photoreceptors in the absence of p53
Marti A., Hafezi F., Lansel N., Hegi M. E., Wenzel A., Grimm C., Niemeyer G., Reme C. E., 1998/04. Investigative Ophthalmology and Visual Science, 39 (5) pp. 846-9.
 
Génétique des tumeurs astrocytaires
François P., Hegi M. E., Meagher-Villemure K., de Tribolet N., 1998. Médecine et Hygiène, 56 (2220) pp. 1594-1597.
 
The mouse ERG before and after light damage is independent of p53
Lansel N., Hafezi F., Marti A., Hegi M., Reme C., Niemeyer G., 1998. Documenta Ophthalmologica, 96 (4) pp. 311-20.
 
Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas
Hegi M. E., zur Hausen A., Ruedi D., Malin G., Kleihues P., 1997/09. International Journal of Cancer, 73 (1) pp. 57-63.
 
Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas
Sure U., Ruedi D., Tachibana O., Yonekawa Y., Ohgaki H., Kleihues P., Hegi M. E., 1997/07. Journal of Neuropathology and Experimental Neurology, 56 (7) pp. 782-9.
 
Gliosarcoma
Biernat W., Hegi M., Aguzzi A., Kleihues P., 1997. pp. 27-28 dans Kleihues P., Cavenee W. C. (eds.) Pathology and genetics of tumours of the nervous system, IARCPress.
 
Hepatic and pulmonary carcinogenicity of methylene chloride in mice: a search for mechanisms
Maronpot R. R., Devereux T. R., Hegi M., Foley J. F., Kanno J., Wiseman R., Anderson M. W., 1995/09. Toxicology, 102 (1-2) pp. 73-81.
 
Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells
Biernat W., Aguzzi A., Sure U., Grant J. W., Kleihues P., Hegi M. E., 1995/09. Journal of Neuropathology and Experimental Neurology, 54 (5) pp. 651-6.
 
Familial brain tumour syndrome associated with a p53 germline deletion of codon 236
Lubbe J., von Ammon K., Watanabe K., Hegi M. E., Kleihues P., 1995/01. Brain Pathology, 5 (1) pp. 15-23.
 
Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation
Hegi M. E., Devereux T. R., Dietrich W. F., Cochran C. J., Lander E. S., Foley J. F., Maronpot R. R., Anderson M. W., Wiseman R. W., 1994/12. Cancer Research, 54 (23) pp. 6257-64.
 
In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice
Harvey M., Sands A. T., Weiss R. S., Hegi M. E., Wiseman R. W., Pantazis P., Giovanella B. C., Tainsky M. A., Bradley A., Donehower L. A., 1993/09. Oncogene, 8 (9) pp. 2457-67.
 
Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice
Hegi M. E., Soderkvist P., Foley J. F., Schoonhoven R., Swenberg J. A., Kari F., Maronpot R., Anderson M. W., Wiseman R. W., 1993/05. Carcinogenesis, 14 (5) pp. 803-10.
 
Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator
Hegi M. E., Fox T. R., Belinsky S. A., Devereux T. R., Anderson M. W., 1993/01. Carcinogenesis, 14 (1) pp. 145-9.
 
Comparison of pulmonary O6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains
Devereux T. R., Belinsky S. A., Maronpot R. R., White C. M., Hegi M. E., Patel A. C., Foley J. F., Greenwell A., Anderson M. W., 1993. Molecular Carcinogenesis, 8 (3) pp. 177-85.
 
Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22
Cannon-Albright L. A., Goldgar D. E., Meyer L. J., Lewis C. M., Anderson D. E., Fountain J. W., Hegi M. E., Wiseman R. W., Petty E. M., Bale A. E. et al., 1992/11. Science, 258 (5085) pp. 1148-52.
 
No measurable increase in thymidine glycol or 8-hydroxydeoxyguanosine in liver DNA of rats treated with nafenopin or choline-devoid low-methionine diet
Hegi M. E., Ulrich D., Sagelsdorff P., Richter C., Lutz W. K., 1990/05. Mutation Research, 238 (3) pp. 325-9.
 
Detection by 32P-postlabeling of thymidine glycol in gamma-irradiated DNA
Hegi M. E., Sagelsdorff P., Lutz W. K., 1989/01. Carcinogenesis, 10 (1) pp. 43-7.
 
In-vitro assays to detect alkylating and mutagenic activities of dietary components nitrosated in situ
Shephard S. E., Hegi M. E., Lutz W. K., 1987. IARC Scientific Publications 84 pp. 232-6.
Transparent     Swiss University
Unicentre  -  CH-1015 Lausanne  -  Suisse  -  Tél. +41 21 692 11 11  -  Fax +41 21 692 20 15